Impairment of vascular-tone regulation and bioavailability of vasodilators (including IDO1 metabolites and NO) is considered central in the development of endothelial dysfunction and diffuse alveolar damage in different conditions, such as COVID-19 [231,232,233,234,235]. This evidence concerns the gene IDO1 and COVID-19.